The verdict
Our read at a glance.
What is established for Egrifta, Egrifta SV, and Egrifta WR in the approved HIV-associated lipodystrophy context, and where broader GH-axis, body-composition, liver, cognition, or wellness claims outrun the evidence.
- The signal
- FDA labels and reviews plus randomized and extension literature support visceral adipose tissue reduction in studied adults with HIV-associated lipodystrophy or excess abdominal fat. Adjacent HIV-NAFLD, liver-fat, muscle-fat, inflammatory-marker, diabetes-safety, and cognition studies are informative but do not establish general wellness outcomes.
- The unknown
- How approved-context body-composition and biomarker signals translate to long-term cardiovascular, metabolic, liver-event, cognition, or hard clinical outcomes outside the studied HIV populations, if at all.
- Our read
- Established for a narrow product-specific use. Stronger than most peptide discourse, but far narrower than the claims it is often used to justify.
The explainer
Watch the 23:27 explainer.
6.0K views · Jul 2026
The mechanism
How it works.
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). It binds GHRH receptors on the pituitary and prompts it to release growth hormone in the body's normal pulse-like pattern, and that growth hormone, along with the IGF-1 it raises, increases the breakdown of fat. This is established human pharmacology, and it is why the drug reduces excess visceral abdominal fat in the HIV-associated lipodystrophy population it is approved for.
Safety & regulatory boundary
The consequential part.
Approved specific use does not equal broad wellness proof. Product identity matters: FDA-approved tesamorelin products are not interchangeable with compounded, research-use, internet-market, CJC-1295, ipamorelin, sermorelin, MK-677, recombinant GH, or other GH-axis products.
What's next
What we're watching.
Post-market safety follow-up, label changes, final reports of required studies, replication in clearly defined non-label populations, and whether HIV-associated NAFLD or cognition signals translate to clinical outcomes rather than biomarkers.
Context
Why this is discussed.
It is one of the few peptide-related medicines with an FDA-approved use and pivotal human data, which makes it easy for online claims to stretch the context or use tesamorelin to validate unrelated GH-axis peptides.
The evidence base
47 cited references.
Regulatory & labels13
National Library of Medicine / FDA label · Revised 2025-03
National Library of Medicine / FDA label · Revised 2024-02
U.S. Food and Drug Administration · 2010-11-10
U.S. Food and Drug Administration · 2010
U.S. Food and Drug Administration · 2010
U.S. Food and Drug Administration · 2010
U.S. Food and Drug Administration · 2010
U.S. Food and Drug Administration · 2010
U.S. Food and Drug Administration · Current database page
U.S. Food and Drug Administration · 2024-02-27
U.S. Food and Drug Administration · 2025-03-25
NIH ClinicalInfo · Updated 2025
HIV Medicine Association / Infectious Diseases Society of America · 2024
Registered trials5
ClinicalTrials.gov · Current registry page
ClinicalTrials.gov · Updated 2026-03-12
ClinicalTrials.gov · Current registry page
ClinicalTrials.gov · Current registry page
ClinicalTrials.gov · Current registry page
Peer-reviewed journals5
Grunfeld, Dritselis, and Kirkpatrick · 2011
Badran et al. · 2026
Fourman et al. · 2020
Clemmons, Miller, and Mamputu · 2017
Indexed literature (PubMed)22
Falutz et al. · 2007
Falutz et al. · 2008
Falutz et al. · 2010
Falutz et al. · 2010
Stanley et al. · 2011
Spooner and Olin · 2012
Stanley et al. · 2014
Mangili et al. · 2015
Fourman et al. · 2017
Adrian, Erlandson, et al. · 2019
Lake et al. · 2021
Rahman et al. · 2023
Russo et al. · 2024
Stanley et al. · 2019
Fourman et al. · 2020
Fourman et al. · 2021
Fourman et al. · 2021
Makimura et al. · 2012
Sponsor & other sources2
CADTH / NCBI Bookshelf · 2016
NIH National Library of Medicine · Updated 2018
Keep reading